⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31267979 | 0.76 | CNR2 (0.49) | — | |
| SCHEMBL18611 | 0.74 | LRRK2 (0.46) | — | |
| SCHEMBL29533314 | 0.74 | LRRK2 (0.46) | — | |
| SCHEMBL2642115 | 0.73 | — | — | |
| SCHEMBL2642118 | 0.73 | — | — | |
| SCHEMBL317521 | 0.73 | — | — | |
| SCHEMBL155110 | 0.73 | — | — | |
| SCHEMBL647575 | 0.73 | — | — | |
| SCHEMBL571240 | 0.73 | — | — | |
| SCHEMBL647576 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151218-A1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | Boehringer Ingelheim International GmbH (DE) | 2023-03-22 | — | — | EP | claimed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190202833-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-04 | — | — | US | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| WO-2007128761-A2 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | claimed |
| CN-101048409-A | Process for the preparation of chiral 8- (3-amino-piperidin-1-yl) -xanthines | BOEHRINGER INGELHEIM INT (DE) | 2007-10-03 | — | — | CN | claimed |
| CN-1980930-A | 8- [ 3-amino-piperidin-1-yl ] -xanthines, their preparation and their use in the form of DPP-IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-06-13 | — | — | CN | claimed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1720875-A1 | 8- [3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
| WO-2005082906-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |